News Headlines Article

Gilead pays startup $123M to develop longer-lasting HIV pill
San Francisco Business Times

HIV patients could one day replace a daily pill for one that would last a week or more, should a new drug development deal struck this week prove successful.

Foster City-based Gilead Sciences Inc. (Nasdaq: GILD) is enlisting Massachusetts startup Lyndra Therapeutics to develop one or more HIV drugs that could last a week, allowing patients to take fewer pills. Gilead will pay Lyndra up to $122.5 million in R&D milestones, as well as commercial royalties on any products produced through the deal.